Pfizer beats Sanofi with Medivation deal for $14B

NEW YORK - Pfizer Inc. agreed to buy Medivation Inc. for about $14 billion, gaining a blockbuster prostate-cancer treatment and leaving French drugmaker Sanofi jilted. Pfizer will pay $81.50 a share in cash, the companies said in a statement on Monday. Shares of Medivation, which closed at $67.16 on Friday, climbed about 20 percent to…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -